Name | Number of supported studies | Average coverage | |
---|---|---|---|
plasmacytoid dendritic cell | 12 studies | 28% ± 12% | |
conventional dendritic cell | 6 studies | 27% ± 16% | |
dendritic cell | 4 studies | 23% ± 3% |
Insufficient scRNA-seq data for expression of TASL at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 100% | 249.93 | 578 / 578 | 93% | 5.77 | 1071 / 1155 |
breast | 78% | 59.22 | 356 / 459 | 96% | 6.81 | 1075 / 1118 |
intestine | 82% | 98.43 | 789 / 966 | 72% | 2.52 | 377 / 527 |
kidney | 65% | 37.25 | 58 / 89 | 83% | 5.24 | 750 / 901 |
stomach | 61% | 32.30 | 220 / 359 | 79% | 2.94 | 226 / 286 |
thymus | 50% | 30.90 | 324 / 653 | 85% | 4.05 | 513 / 605 |
adrenal gland | 86% | 57.89 | 221 / 258 | 45% | 0.99 | 103 / 230 |
brain | 40% | 26.94 | 1044 / 2642 | 91% | 5.26 | 640 / 705 |
uterus | 44% | 17.99 | 74 / 170 | 76% | 2.48 | 351 / 459 |
esophagus | 45% | 20.01 | 644 / 1445 | 74% | 2.06 | 135 / 183 |
prostate | 67% | 36.61 | 164 / 245 | 50% | 1.17 | 252 / 502 |
bladder | 52% | 37.10 | 11 / 21 | 63% | 2.38 | 317 / 504 |
pancreas | 26% | 13.67 | 85 / 328 | 86% | 4.68 | 153 / 178 |
lymph node | 0% | 0 | 0 / 0 | 100% | 26.17 | 29 / 29 |
spleen | 100% | 659.19 | 241 / 241 | 0% | 0 | 0 / 0 |
peripheral blood | 100% | 1186.67 | 928 / 929 | 0% | 0 | 0 / 0 |
skin | 24% | 8.42 | 428 / 1809 | 72% | 3.58 | 340 / 472 |
ovary | 19% | 7.94 | 34 / 180 | 77% | 2.56 | 330 / 430 |
tonsil | 0% | 0 | 0 / 0 | 91% | 5.13 | 41 / 45 |
adipose | 91% | 103.77 | 1091 / 1204 | 0% | 0 | 0 / 0 |
liver | 43% | 19.88 | 98 / 226 | 42% | 1.13 | 170 / 406 |
blood vessel | 70% | 55.47 | 928 / 1335 | 0% | 0 | 0 / 0 |
heart | 28% | 13.15 | 243 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 15% | 0.33 | 12 / 80 |
muscle | 3% | 1.10 | 27 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0045087 | Biological process | innate immune response |
GO_0034157 | Biological process | positive regulation of toll-like receptor 7 signaling pathway |
GO_0034121 | Biological process | regulation of toll-like receptor signaling pathway |
GO_0035751 | Biological process | regulation of lysosomal lumen pH |
GO_0034161 | Biological process | positive regulation of toll-like receptor 8 signaling pathway |
GO_0045089 | Biological process | positive regulation of innate immune response |
GO_0043231 | Cellular component | intracellular membrane-bounded organelle |
GO_0005654 | Cellular component | nucleoplasm |
GO_0036020 | Cellular component | endolysosome membrane |
GO_0005515 | Molecular function | protein binding |
Gene name | TASL |
Protein name | TLR adapter interacting with SLC15A4 on the lysosome |
Synonyms | CXorf21 |
Description | FUNCTION: Innate immune adapter that mediates the recruitment and activation of IRF5 downstream of endolysosomal toll-like receptors TLR7, TLR8 and TLR9 . Following recruitment to endolysosome by SLC15A4 downstream of TLR7, TLR8 and TLR9, specifically recruits IRF5 transcription factor via its pLxIS motif, leading to IRF5 activation and subsequent expression of type I interferons . Plays a role in the regulation of endolysosomal pH in immune cells such as B-cells, dendritic cells and monocytes . . |
Accessions | Q9HAI6 ENST00000378962.4 |